{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:08:08Z","timestamp":1792818488378,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a relatively new class of drugs for treatment of Type 2 Diabetes mellitus (T2DM). They have proven to be excellent drugs not only for the results on glycemic control but also for weight loss, cardiovascular protection and several other potential metabolic effects. In contrast, the effects of GLP-1RAs drugs on bone metabolism and bone mineral density (BMD) remain less clearly defined. This narrative review aimed to explore the relationship between GLP-1RAs and bone in T2DM patients by reviewing clinical studies which assessed the effects of GLP-1RAs on BMD, markers of bone turnover and fragility fractures. In vitro and animal studies have demonstrated that GLP-1RAs treatment promotes bone formation and inhibits bone resorption. However, in humans, GLP-1RAs therapy has been shown to primarily stimulate bone resorption, as evidenced by a significant increase in type I collagen C-terminal cross-linked telopeptide levels, while promoting new bone formation to a lesser extent. Clinical studies indicate that GLP-1RAs therapy, in both diabetic and non-diabetic patients, results in a reduction in BMD, which is more pronounced at skeletal sites subjected to higher mechanical loading, such as the femur and tibia, and appears to correlate with the degree of weight loss. Furthermore, in the studies reviewed, parameters related to bone quality and strength, such as Trabecular bone score (TBS), microindentation, High-resolution peripheral Quantitative Computed Tomography (HR-pQCT), and Radiofrequency Echographic Multi Spectrometry (REMS) remain unaffected by GLP-1RAs. Additionally, the incidence of fragility fractures does not increase.<\/jats:p>","DOI":"10.1007\/s12020-025-04253-4","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T19:12:54Z","timestamp":1746731574000},"page":"30-38","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of type 2 diabetes mellitus: friends or foes to bone health? a narrative review of clinical studies"],"prefix":"10.1007","volume":"89","author":[{"given":"Antonella","family":"Al Refaie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Baldassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Mondillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gonnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ceccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Tarquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Gonnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Gennari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4163-7289","authenticated-orcid":false,"given":"Carla","family":"Caffarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"4253_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/aje\/kwm106","volume":"166","author":"M Janghorbani","year":"2007","unstructured":"M. Janghorbani, R.M. Van Dam, W.C. Willett, F.B. Hu, Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am. J. Epidemiol. 166, 495\u2013505 (2007). https:\/\/doi.org\/10.1093\/aje\/kwm106.","journal-title":"Am. J. Epidemiol."},{"key":"4253_CR2","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1007\/s00198-019-05122-3","volume":"30","author":"C Teb\u00e9","year":"2019","unstructured":"C. Teb\u00e9, D. Mart\u00ednez-Laguna, C. Carbonell-Abella, C. Reyes, V. Moreno, A. Diez-Perez, G.S. Collins, D. Prieto-Alhambra, The association between type 2 diabetes mellitus, hip fracture, and post-hip fracture mortality: a multi-state cohort analysis. Osteoporos. Int. 30, 2407\u20132415 (2019). https:\/\/doi.org\/10.1007\/s00198-019-05122-3.","journal-title":"Osteoporos. Int."},{"key":"4253_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3390\/medicina60030393","volume":"60","author":"A Wikarek","year":"2024","unstructured":"A. Wikarek, M. Grabarczyk, K. Klimek, A. Janoska-Gawro\u0144ska, M. Suchodolska, M. Holecki, Effect of drugs used in pharmacotherapy of type 2 diabetes on bone density and risk of bone fractures. Medicina 60, 393 (2024). https:\/\/doi.org\/10.3390\/medicina60030393.","journal-title":"Medicina"},{"key":"4253_CR4","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"N. Marx, M. Federici, K. Sch\u00fctt, D. M\u00fcller-Wieland, R.A. Ajjan, M.J. Antunes, R.M. Christodorescu et al., ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur. Heart J. 44, 4043\u20134140 (2023). https:\/\/doi.org\/10.1093\/eurheartj\/ehad192.","journal-title":"Eur. Heart J."},{"issue":"Supplement_1","key":"4253_CR5","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee, 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025. Diabetes Care 48(Supplement_1), S181\u2013S206 (2025). https:\/\/doi.org\/10.2337\/dc25-S009.","journal-title":"Diabetes Care"},{"key":"4253_CR6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.21037\/atm.2019.06.74","volume":"7","author":"L Zhang","year":"2019","unstructured":"L. Zhang, P. Li, Z. Tang, Q. Dou, B. Feng, Effects of GLP-1 receptor analogue liraglutide and DPP-4 inhibitor vildagliptin on the bone metabolism in ApoE\u2212\/\u2212 mice. Ann. Transl. Med. 7, 369 (2019). https:\/\/doi.org\/10.21037\/atm.2019.06.74.","journal-title":"Ann. Transl. Med."},{"key":"4253_CR7","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1089\/dna.2018.4397","volume":"37","author":"L Gao","year":"2018","unstructured":"L. Gao, S.L. Li, Y.K. Li, Liraglutide promotes the osteogenic differentiation in MC3T3-E1 cells via regulating the expression of Smad2\/3 through PI3K\/Akt and Wnt\/\u03b2-catenin pathways. DNA. Cell. Biol. 37, 1031\u20131043 (2018). https:\/\/doi.org\/10.1089\/dna.2018.4397.","journal-title":"DNA. Cell. Biol."},{"key":"4253_CR8","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00223-009-9220-3","volume":"84","author":"B Nuche-Berenguer","year":"2009","unstructured":"B. Nuche-Berenguer, P. Moreno, P. Esbrit, S. Dapia, J.R. Caeiro, J. Cancelas, J.J. Haro-Mora, M.L. Villanueva-Penacarrillo, Effect of glp-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif. Tissue Int. 84, 453\u2013461 (2009). https:\/\/doi.org\/10.1007\/s00223-009-9220-3.","journal-title":"Calcif. Tissue Int."},{"key":"4253_CR9","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/jbmr.1898","volume":"28","author":"X Ma","year":"2013","unstructured":"X. Ma, J. Meng, M. Jia, L. Bi, Y. Zhou, Y. Wang, J. Hu, G. He, X. Luo, Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats. J. Bone Miner. Res. 28, 1641\u20131652 (2013). https:\/\/doi.org\/10.1002\/jbmr.1898.","journal-title":"J. Bone Miner. Res."},{"key":"4253_CR10","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00404-018-4776-7","volume":"297","author":"E Eminov","year":"2018","unstructured":"E. Eminov, I. Hortu, L. Akman, O. Erbas, A. Yavasoglu, T. Cirpan, Exenatide preserves trabecular bone microarchitecture in experimental ovariectomized rat model. Arch. Gynecol. Obstet. 297, 1587\u20131593 (2018). https:\/\/doi.org\/10.1007\/s00404-018-4776-7.","journal-title":"Arch. Gynecol. Obstet."},{"key":"4253_CR11","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1177\/15353702211032133","volume":"246","author":"Y Zhou","year":"2021","unstructured":"Y. Zhou, X. Xue, Y. Guo, H. Liu, Z. Hou, Z. Chen, N. Wang, F. Li, Y. Wang, A quinoxaline-based compound ameliorates bone loss in ovariectomized mice. Exp. Biol. Med. 246, 2502\u20132510 (2021). https:\/\/doi.org\/10.1177\/15353702211032133.","journal-title":"Exp. Biol. Med."},{"key":"4253_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s12020-014-0361-4","volume":"48","author":"B Su","year":"2015","unstructured":"B. Su, H. Sheng, M. Zhang, L. Bu, P. Yang, L. Li, F. Li, C. Sheng, Y. Han, S. Qu, J. Wang, Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists\u2019 treatment: a meta-analysis of randomized controlled trials. Endocrine 48, 107\u2013115 (2015). https:\/\/doi.org\/10.1007\/s12020-014-0361-4.","journal-title":"Endocrine"},{"key":"4253_CR13","doi-asserted-by":"publisher","first-page":"e3843","DOI":"10.1002\/dmrr.384","volume":"40","author":"HJ Kim","year":"2024","unstructured":"H.J. Kim, S.A. Choi, M.S. Gu, S.Y. Ko, J.H. Kwon, J.Y. Han, J.H. Kim, M.G. Kim, Effects of glucagon-like peptide-1 receptor agonist on bone mineral density and bone turnover markers: a meta-analysis. Diabetes. Metab. Res. Rev. 40, e3843 (2024). https:\/\/doi.org\/10.1002\/dmrr.384.","journal-title":"Diabetes. Metab. Res. Rev."},{"key":"4253_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00223-023-01150-8","volume":"114","author":"J Herrou","year":"2024","unstructured":"J. Herrou, G. Mabilleau, J.M. Lecerf, T. Thomas, E. Biver, J. Paccou, Narrative review of effects of glucagon-like peptide-1 receptor agonists on bone health in people living with obesity. Calcif. Tissue Int. 114, 86\u201397 (2024). https:\/\/doi.org\/10.1007\/s00223-023-01150-8.","journal-title":"Calcif. Tissue Int."},{"key":"4253_CR15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/j.1463-1326.2010.01355.x","volume":"13","author":"MC Bunck","year":"2011","unstructured":"M.C. Bunck, B. Eliasson, A. Corn\u00e9r, R.J. Heine, R.M. Shaginian, M.R. Taskinen, H. Yki-J\u00e4rvinen, U. Smith, M. Diamant, Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes Obes. Metab. 13, 374\u2013377 (2011). https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01355.x.","journal-title":"Diabetes Obes. Metab."},{"key":"4253_CR16","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00592-015-0792-2","volume":"52","author":"R Li","year":"2015","unstructured":"R. Li, W. Xu, S. Luo, H. Xu, G. Tong, L. Zeng, D. Zhu, J. Weng, Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes. Acta. Diabetol. 52, 1083\u20131091 (2015). https:\/\/doi.org\/10.1007\/s00592-015-0792-2.","journal-title":"Acta. Diabetol."},{"key":"4253_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s00223-015-9993-5","volume":"97","author":"JH Driessen","year":"2025","unstructured":"J.H. Driessen, R.M. Henry, H.A. van Onzenoort, A. Lalmohamed, A.M. Burden, D. Prieto-Alhambra, C. Neef, H.G. Leufkens, F. de Vries, Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis. Calcif. Tissue Int. 97, 104\u2013112 (2025). https:\/\/doi.org\/10.1007\/s00223-015-9993-5.","journal-title":"Calcif. Tissue Int."},{"key":"4253_CR18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.4158\/EP15758.OR","volume":"22","author":"MP Gilbert","year":"2016","unstructured":"M.P. Gilbert, M. Marre, J.J. Holst, A. Garber, F.M. Baeres, H. Thomsen, R.E. Pratley, Comparison of the long term effects of liraglutide and glimepiride monotherapy on bone mineral density in patients with type 2 diabetes. Endocr. Pract. 22, 406\u2013411 (2016). https:\/\/doi.org\/10.4158\/EP15758.OR.","journal-title":"Endocr. Pract."},{"key":"4253_CR19","doi-asserted-by":"publisher","first-page":"115197","DOI":"10.1016\/j.bone.2019.115197","volume":"132","author":"K Hygum","year":"2020","unstructured":"K. Hygum, T. Harsl\u00f8f, N.R. J\u00f8rgensen, J. Rungby, S.B. Pedersen, B.L. Langdahl, Bone resorption is unchanged by liraglutide in type 2 diabetes patients: a randomised controlled trial. Bone 132, 115197 (2020). https:\/\/doi.org\/10.1016\/j.bone.2019.115197.","journal-title":"Bone"},{"key":"4253_CR20","doi-asserted-by":"publisher","first-page":"3361309","DOI":"10.1155\/2021\/3361309","volume":"17","author":"TT Cai","year":"2021","unstructured":"T.T. Cai, H.Q. Li, L.L. Jiang, H.Y. Wang, M.H. Luo, X.F. Su, J.H. Ma, Effects of GLP-1 receptor agonists on bone mineral density in patients with type 2 diabetes mellitus: a 52-week clinical study. Biomed. Res. Int. 17, 3361309 (2021). https:\/\/doi.org\/10.1155\/2021\/3361309.","journal-title":"Biomed. Res. Int."},{"key":"4253_CR21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/dom.14568","volume":"24","author":"NJ Johansen","year":"2022","unstructured":"N.J. Johansen, T.F. Dejgaard, A. Lund, C. Schl\u00fcntz, B. Hartmann, J.J. Holst, T. Vilsb\u00f8ll, H.U. Andersen, F.K. Knop, Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes. Diabetes Obes. Metab. 24, 221\u2013227 (2022). https:\/\/doi.org\/10.1111\/dom.14568.","journal-title":"Diabetes Obes. Metab."},{"key":"4253_CR22","doi-asserted-by":"publisher","first-page":"882998","DOI":"10.3389\/fendo.2022.882998","volume":"13","author":"ZK Al-Mashhadi","year":"2022","unstructured":"Z.K. Al-Mashhadi, R. Viggers, R. Fuglsang-Nielsen, P. Vestergaard, S. Gregersen, J. Starup-Linde, The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: a Danish nationwide cohort study. Front Endocrinol. 13, 882998 (2022). https:\/\/doi.org\/10.3389\/fendo.2022.882998.","journal-title":"Front Endocrinol."},{"key":"4253_CR23","doi-asserted-by":"publisher","first-page":"e35394","DOI":"10.1097\/MD.0000000000035394","volume":"102","author":"OZ Akyay","year":"2023","unstructured":"O.Z. Akyay, Z. Canturk, A. Selek, B. Cetinarslan, \u0130 Tarkun, Y. Cakmak, C. Baydemir, The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus. Medicine 102, e35394 (2023). https:\/\/doi.org\/10.1097\/MD.0000000000035394.","journal-title":"Medicine"},{"key":"4253_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/DMSO.S389964","volume":"16","author":"CF Huang","year":"2023","unstructured":"C.F. Huang, T.Y. Mao, S.J. Hwang, The effects of switching from dipeptidyl peptidase-4 inhibitors to glucagon-like peptide-1 receptor agonists on bone mineral density in diabetic patients. Diabetes Metab. Syndr. Obes. 16, 31\u201336 (2023). https:\/\/doi.org\/10.2147\/DMSO.S389964.","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"4253_CR25","doi-asserted-by":"publisher","first-page":"102624","DOI":"10.1016\/j.eclinm.2024.102624","volume":"72","author":"MS Hansen","year":"2024","unstructured":"M.S. Hansen, E.M. W\u00f6lfel, S. Jeromdesella, J.K. M\u00f8ller, C. Ejersted, N.R. J\u00f8rgensen, R. Eastell, S.G. Hansen, M. Frost, Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial. EClinicalMedicine 72, 102624 (2024). https:\/\/doi.org\/10.1016\/j.eclinm.2024.102624.","journal-title":"EClinicalMedicine"},{"key":"4253_CR26","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s00223-024-01240-1","volume":"116","author":"A Al Refaie","year":"2024","unstructured":"A. Al Refaie, L. Baldassini, C. Mondillo, E. Ceccarelli, R. Tarquini, L. Gennari, S. Gonnelli, C. Caffarelli, Glucagon-like Peptide-1 receptor agonists and diabetic osteopathy: another positive effect of incretines? A 12 months longitudinal study. Calcif. Tissue Int. 116, 160\u2013168 (2024). https:\/\/doi.org\/10.1007\/s00223-024-01240-1.","journal-title":"Calcif. Tissue Int."},{"key":"4253_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40520-021-01889-w","volume":"34","author":"C Caffarelli","year":"2022","unstructured":"C. Caffarelli, M.D. Tomai Pitinca, A. Al Refaie, E. Ceccarelli, S. Gonnelli, Ability of radiofrequency echographic multispectrometry to identify osteoporosis status in elderly women with type 2 diabetes. Aging Clin. Exp. Res. 34, 121\u2013127 (2022). https:\/\/doi.org\/10.1007\/s40520-021-01889-w.","journal-title":"Aging Clin. Exp. Res."},{"key":"4253_CR28","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1210\/jc.2015-1176","volume":"100","author":"EW Lepsen","year":"2015","unstructured":"E.W. Lepsen, J.R. Lundgren, B. Hartmann, O. Pedersen, T. Hansen, N.R. J\u00f8rgensen, J.E. Jensen, J.J. Holst, S. Madsbad, S.S. Torekov, GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. J. Clin. Endocrinol. Metab. 100, 2909\u20132917 (2015). https:\/\/doi.org\/10.1210\/jc.2015-1176.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4253_CR29","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1080\/07315724.2009.10719788","volume":"28","author":"PS Hinton","year":"2009","unstructured":"P.S. Hinton, J.D. LeCheminant, B.K. Smith, R.S. Rector, J.E. Donnelly, Weight loss-induced alterations in serum markers of bone turnover persist during weight maintenance in obese men and women. J. Am. Coll. Nutr. 28, 565\u2013573 (2009). https:\/\/doi.org\/10.1080\/07315724.2009.10719788.","journal-title":"J. Am. Coll. Nutr."},{"key":"4253_CR30","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1002\/jbmr.2564","volume":"30","author":"J Zibellini","year":"2015","unstructured":"J. Zibellini, R.V. Seimon, C.M. Lee, A.A. Gibson, M.S. Hsu, A. Sainsbury, A.P. Hills, Does diet-induced weight loss lead to bone loss in overweight or obese adults? A systematic review and meta-analysis of clinical trials. J. Bone Miner. Res. 30, 2168\u20132178 (2015). https:\/\/doi.org\/10.1002\/jbmr.2564.","journal-title":"J. Bone Miner. Res."},{"key":"4253_CR31","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1007\/s00198-022-06398-8","volume":"33","author":"SW Lee","year":"2022","unstructured":"S.W. Lee, K. Han, H.S. Kwon, Weight change and the risk of hip fractures in patients with type 2 diabetes: a nationwide cohort study. Osteoporos. Int. 33, 1755\u20131767 (2022). https:\/\/doi.org\/10.1007\/s00198-022-06398-8.","journal-title":"Osteoporos. Int."},{"key":"4253_CR32","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/jbmr.1483","volume":"27","author":"AV Schwartz","year":"2012","unstructured":"A.V. Schwartz, K.C. Johnson, S.E. Kahn, J.A. Shepherd, M.C. Nevitt, A.L. Peters, M.P. Walkup, A. Hodges, C.C. Williams, G.A. Bray, Look AHEAD Research Group, Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: results from the look AHEAD randomized trial. J. Bone Miner. Res. 27, 619\u2013627 (2012). https:\/\/doi.org\/10.1002\/jbmr.1483.","journal-title":"J. Bone Miner. Res."},{"key":"4253_CR33","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/ar.a.10119","volume":"275","author":"HM Frost","year":"2003","unstructured":"H.M. Frost, Bone\u05f3s mechanostat: a 2003 update. Anat. Rec. Part A Discov. Mol. Cell. Evol. Biol. 275, 1081\u20131101 (2003). https:\/\/doi.org\/10.1002\/ar.a.10119.","journal-title":"Anat. Rec. Part A Discov. Mol. Cell. Evol. Biol."},{"key":"4253_CR34","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/1753-0407.12102","volume":"6","author":"G Mabilleau","year":"2016","unstructured":"G. Mabilleau, A. Mieczkowska, D. Chappard, Use of glucagon like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials. J. Diabetes 6, 260\u2013266 (2016). https:\/\/doi.org\/10.1111\/1753-0407.12102.","journal-title":"J. Diabetes"},{"key":"4253_CR35","doi-asserted-by":"publisher","first-page":"735824","DOI":"10.3389\/fendo.2021.735824","volume":"14","author":"YS Zhang","year":"2021","unstructured":"Y.S. Zhang, Y.D. Zheng, Y. Yuan, S.C. Chen, B.C. Xie, Effects of anti-diabetic drugs on fracture risk: a systematic review and net work meta-analysis. Front. Endocrinol. 14, 735824 (2021). https:\/\/doi.org\/10.3389\/fendo.2021.735824. 27.","journal-title":"Front. Endocrinol."},{"key":"4253_CR36","doi-asserted-by":"publisher","first-page":"e3168","DOI":"10.1002\/dmrr.3168","volume":"35","author":"L Cheng","year":"2019","unstructured":"L. Cheng, Y. Hu, Y.Y. Li, X. Cao, N. Bai, T.T. Lu, G.Q. Li, N. Li, A.N. Wang, X.M. Mao, Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Metab. Res. Rev. 35, e3168 (2019). https:\/\/doi.org\/10.1002\/dmrr.3168.","journal-title":"Diabetes Metab. Res. Rev."},{"key":"4253_CR37","doi-asserted-by":"publisher","first-page":"117338","DOI":"10.1016\/j.bone.2024.117338","volume":"192","author":"Y Zhang","year":"2025","unstructured":"Y. Zhang, G. Chen, W. Wang, D. Yang, D. Zhu, Y. Jing, Association of Glucagon-like peptide-1 receptor agonists use with fracture risk in type 2 diabetes: a meta-analysis of randomized controlled trials. Bone 192, 117338 (2025). https:\/\/doi.org\/10.1016\/j.bone.2024.117338.","journal-title":"Bone"},{"key":"4253_CR38","doi-asserted-by":"publisher","first-page":"7399","DOI":"10.3390\/jcm12237399","volume":"12","author":"AI Trandafir","year":"2023","unstructured":"A.I. Trandafir, O.C. Sima, A.M. Gheorghe, A. Ciuche, A.P. Cucu, C. Nistor, M. Carsote, Trabecular bone score (TBS) in individuals with type 2 diabetes mellitus: an updated review. J. Clin. Med. 12, 7399 (2023). https:\/\/doi.org\/10.3390\/jcm12237399.","journal-title":"J. Clin. Med."},{"key":"4253_CR39","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.bonr.2016.07.004","volume":"5","author":"A Diez-Perez","year":"2016","unstructured":"A. Diez-Perez, M.L. Bouxsein, E.F. Eriksen, S. Khosla, J.S. Nyman, S. Papapoulos, S.Y. Tang, Technical note: Recommendations for a standard procedure to assess cortical bone at the tissue-level in vivo using impact microindentation. Bone Rep. 5, 181\u2013185 (2016). https:\/\/doi.org\/10.1016\/j.bonr.2016.07.004.","journal-title":"Bone Rep."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04253-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04253-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04253-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T06:49:15Z","timestamp":1751611755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04253-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["4253"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04253-4","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"4 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}